Answers are grounded in this paper and cite their sources.
Demonstrates that compound (S,S)-15 reduces tumor volume in colorectal cancer, highlighting its therapeutic promise.
High Resolution Image Download MS PowerPoint Slide Dishevelled (DVL) proteins are key mediators of the Wnt/β-catenin signaling pathway, involved in signal transduction from membrane receptors to intracellular effectors. DVL up-regulation has often been correlated with tumor progression and metastasis. DVL1 was found overexpressed in multidrug-resistant colorectal cancer (CRC) cells. Here, we describe the synthesis of new indole-2-carboxamides 2–18 as DVL1 inhibitors. Compound ( S, S )- 15 showed potent DVL1 inhibition with IC 50 of 0.97 ± 0.21 μM and specific binding to the DVL1 PDZ domain. ( S, S )- 15 strongly reduced β-catenin expression in HCT116 CRC cells and significantly decreased tumor volume and weight in a xenograft model. Additionally, ( S, S )- 15 inhibited P-glycoprotein (P-gp), restoring sensitivity to doxorubicin (DOX) in HT29/DX CRC chemoresistant cells. ( S, S )- 15 demonstrated high metabolic stability in human liver microsomes, and an acceptable pharmacokinetic profile following IV administration in mice. Our findings indicate that compound ( S, S )- 15 represents a promising dual-targeting antitumor candidate for CRC treatment.
No takes yet. Share an insight, caveat, or question.
Puxeddu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: